U.S. flag

An official website of the United States government

We are planning the future of MedGen. Fill out this survey or email us at medgen_help@ncbi.nlm.nih.gov to tell us how it can work better for you.

Recurrent High Risk Chronic Myelomonocytic Leukemia

MedGen UID:
1711123
•Concept ID:
C5238539
•
Neoplastic Process

Definition

The reemergence of high risk chronic myelomonocytic leukemia after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent High Risk Chronic Myelomonocytic Leukemia

Recent clinical studies

Etiology

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G
Br J Haematol 2024 Mar;204(3):898-909. Epub 2023 Nov 10 doi: 10.1111/bjh.19193. PMID: 37946611
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL, Berger KR, Mazzone A, Potluri S, Ordog T, Robertson KD, Marks DL, Fernandez-Zapico ME, Gaspar-Maia A, Patnaik MM
Nat Commun 2022 Mar 17;13(1):1434. doi: 10.1038/s41467-022-29142-6. PMID: 35301312Free PMC Article
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW, Collin M, Horwitz MS
Semin Hematol 2017 Apr;54(2):81-86. Epub 2017 May 10 doi: 10.1053/j.seminhematol.2017.05.002. PMID: 28637621Free PMC Article
Extramedullary Manifestations of Myeloid Neoplasms.
Wilson CS, Medeiros LJ
Am J Clin Pathol 2015 Aug;144(2):219-39. doi: 10.1309/AJCPO58YWIBUBESX. PMID: 26185307

Diagnosis

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
Extramedullary Manifestations of Myeloid Neoplasms.
Wilson CS, Medeiros LJ
Am J Clin Pathol 2015 Aug;144(2):219-39. doi: 10.1309/AJCPO58YWIBUBESX. PMID: 26185307
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
Thiede Ch, Lutterbeck K, Oelschlägel U, Kiehl M, Steudel Ch, Platzbecker U, Brendel C, Fauser AA, Neubauer A, Ehninger G, Bornhäuser M
Ann Hematol 2002;81 Suppl 2:S27-8. PMID: 12611065

Therapy

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G
Br J Haematol 2024 Mar;204(3):898-909. Epub 2023 Nov 10 doi: 10.1111/bjh.19193. PMID: 37946611
Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL, Gao WH, Wang LN, Wan M, Wang L, Hu J
Transplant Cell Ther 2023 Aug;29(8):512.e1-512.e8. Epub 2023 May 30 doi: 10.1016/j.jtct.2023.05.017. PMID: 37263418
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Wattebled KJ, Drumez E, Coiteux V, Magro L, Srour M, Chauvet P, Quesnel B, Duhamel A, Yakoub-Agha I, Beauvais D
Ann Hematol 2022 Jun;101(6):1321-1331. Epub 2022 Mar 29 doi: 10.1007/s00277-022-04821-y. PMID: 35352216
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP
Am J Hematol 2019 Jul;94(7):757-766. Epub 2019 May 7 doi: 10.1002/ajh.25486. PMID: 30963592

Prognosis

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G
Br J Haematol 2024 Mar;204(3):898-909. Epub 2023 Nov 10 doi: 10.1111/bjh.19193. PMID: 37946611
Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL, Gao WH, Wang LN, Wan M, Wang L, Hu J
Transplant Cell Ther 2023 Aug;29(8):512.e1-512.e8. Epub 2023 May 30 doi: 10.1016/j.jtct.2023.05.017. PMID: 37263418
Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A
Genes Chromosomes Cancer 2019 Oct;58(10):698-704. Epub 2019 May 1 doi: 10.1002/gcc.22761. PMID: 30994218
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ
Biol Blood Marrow Transplant 2014 Apr;20(4):549-55. Epub 2014 Jan 16 doi: 10.1016/j.bbmt.2014.01.009. PMID: 24440648Free PMC Article
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.
Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, Sandmaier BM, Warren EH, Storb R, Appelbaum FR, Deeg HJ
Biol Blood Marrow Transplant 2011 Jun;17(6):908-15. Epub 2010 Oct 6 doi: 10.1016/j.bbmt.2010.09.018. PMID: 20932924Free PMC Article

Clinical prediction guides

Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G
Br J Haematol 2024 Mar;204(3):898-909. Epub 2023 Nov 10 doi: 10.1111/bjh.19193. PMID: 37946611
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ
Biol Blood Marrow Transplant 2014 Apr;20(4):549-55. Epub 2014 Jan 16 doi: 10.1016/j.bbmt.2014.01.009. PMID: 24440648Free PMC Article
Implication of early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation in children with leukemia.
Han DK, Baek HJ, Kim SY, Hwang TJ, Kook H
Yonsei Med J 2013 Jan 1;54(1):62-70. doi: 10.3349/ymj.2013.54.1.62. PMID: 23225800Free PMC Article
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.
Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, Sandmaier BM, Warren EH, Storb R, Appelbaum FR, Deeg HJ
Biol Blood Marrow Transplant 2011 Jun;17(6):908-15. Epub 2010 Oct 6 doi: 10.1016/j.bbmt.2010.09.018. PMID: 20932924Free PMC Article
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H
Cancer 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416. PMID: 12767088

Supplemental Content

Table of contents

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    PreferencesTurn off
    External link. Please review our privacy policy.